AGENDA

8:00 – 8:15 Welcome/SARC Update  
Laurence Baker  
Chair, SARC Board of Directors

8:15 – 8:45 Chawla/Rosenfeld Developmental Therapeutics Symposium (Part 1)  
Laboratory Investigation of Resistant GIST  
Jonathan Fletcher

8:45– 10:15 Review of Ongoing SARC Trials
- SARC 003 Phase 2 Gemcitabine/Docetaxel in Bone Sarcoma  
  Lee Helman
- SARC 004 Phase 2 Neoadjuvant Imatinib in DFSP  
  Scott Schuetze
- SARC 005 Phase 2 Adjuvant Therapy High Risk Uterine Leiomyosarcoma  
  TBD
- SARC 006 Phase 2 MPNST: Sporadic versus NF1 associated  
  Lee Helman
- SARC 007 Phase 2 Perifosine in chemoinsensitive sarcoma  
  Jonathan Trent
- SARC 009 Phase 2 Dasatinib in metastatic sarcoma  
  Scott Schuetze
- SARC 011 Phase 2 IGF-1R in selected sarcomas  
  Alberto Pappo
- SARC011 Companion Biology Protocol  
  Lee Helman
- SARC 012 Phase 2 Src kinase Inhibitor Recurrent Osteosarcoma Localized to Lung  
  Su Kim

10:15 – 10:45 Chawla/Rosenfeld Developmental Therapeutics Symposium (Part 2)  
New Approaches to GIST  
Meg von Mehren

10:45—11:15 Review of Pending Trials
- SARC 013 Phase 3 IGF-1R/Ewings  
  Herbert Jürgens*  
  Paul Meyers  
  Shreyas Patel
- SARC014 Phase 1 IGF-1R/Rapamycin  
  Richard Gorlick
- SARC015 Phase 2R1507 in WT GIST  
  Meg von Mehren*  
  Katie Janeway*
- SARC016 Phase 2 Everolimus/MPNST  
  Lee Helman
- SARC018 Phase 2 Surgery/Radiation  
  Robert Benjamin

11:00 – 11:30 SARC Restructuring
- Participating Committee  
  Suzanne George
- Medical Officer and New Concepts  
  Denise Reinke

11:30-12:00 Closed Session: SARC Business Update  
(SARC Participants Only)